Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Stop of treatment in COVID-19 study
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19Phase II study assessing BI 764198, a novel first-in-class compound, for patients hospitalized with COVID-19 with respiratory complications discontinued due to lack of efficacy in this indicationBoehringer Ingelheim remains committed to other research and development efforts in COVID-19 including new SARS-CoV-2 neutralizing antibodies (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2021 Category: Research Source Type: news

Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of ObesityThe research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim ’s research into approaches with first in class potential for the treatment of obesity Obesity is a complex cardiometabolic disease with growing global prevalence and limited treatment options that are not sufficiently effective or are associated with adverse events (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 1, 2021 Category: Research Source Type: news

ATM-Ranking-2021
Access-To-Medicine: Ranking Progress and Focus on Early-Phase R&DBoehringer Ingelheim climbs two more places to rank 12 in 2021 Access-To-Medicine Index New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected in index criteriaWide range of projects addressing health challenges in low- and middle-income countries recognized (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 26, 2021 Category: Research Source Type: news

global-top-employer
Award: Boehringer Ingelheim is Global Top Employer 2021 Boehringer Ingelheim is one of sixteen top employers worldwide Awards in 27 countries and in Europe and the Latin America and Asia-Pacific regions Boehringer Ingelheim performs particularly well in strategy, corporate culture and employee involvement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 21, 2021 Category: Research Source Type: news

Boehringer Ingelheim partners with PetMedix
Boehringer Ingelheim has entered into a partnership with PetMedix, a UK based research and development stage biopharmaceutical company.Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim ’s refocused strategy. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim receives EMA marketing authorization for NexGard® COMBO, the first isoxazoline-based full endectocide for catsThe product features a triple action formula that includes esafoxolaner – the newly developed form of afoxolaner - combined with eprinomectin and praziquantel.This innovative broad spectrum topical parasiticide is easy and convenient for cat owners.It kills a wider range of parasites than any other product on the market, covering core external parasites like fleas and ticks as well as internal parasites, including tapeworms. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancersLatest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim ’s position in the cancer vaccine and T-cell engager spacesAgreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio ’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach (Source: Boehrin...
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

Partnering-with-google-in-quantum-computing
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D Quantum computing offers the potential to significantly accelerate and optimize the discovery of future new medicines for patientsScientists from both companies will be breaking new ground in the application of quantum computing to molecular dynamics simulationsBoehringer Ingelheim has set up a dedicated Quantum Lab with leading experts (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2021 Category: Research Source Type: news

Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol ® IleitisThe Paul Ehrlich Institute (PEI) accepted new language on the label of Enterisol ® Ileitis, the only global oral live Lawsonia intracellularis vaccine to control Ileitis in swine.Boehringer Ingelheim strives to continuously bring innovation to the market to improve animal health. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 21, 2020 Category: Research Source Type: news

SARS-CoV-2-Neutralizing-Antibody-enters-Clinical-Phase
New SARS-CoV-2 Neutralizing Antibody enters Clinical PhaseCologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and preventionBI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical researchPhase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2020 Category: Research Source Type: news

Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates Acquisition will add another key dimension to Boehringer Ingelheim ’s focus on patients with difficult-to-treat solid tumors NBE-Therapeutics ’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform NBE-Therapeutics ’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 10, 2020 Category: Research Source Type: news

Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to Acquire Labor Dr. Merk& Kollegen to Strengthen its Next Generation Cancer Immunology ProgramBoehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk& KollegenTransaction expands Boehringer Ingelheim ’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatmentsBoehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 9, 2020 Category: Research Source Type: news

Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health.The International Poultry Council represents a unified and harmonized voice of the poultry industry. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2020 Category: Research Source Type: news

collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer New collaboration strengthens Boehringer Ingelheim ’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancersProxygen ’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis targeting chimeras (PROTACs) in the aim of degrading cancer drivers that were previously considered undruggable (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2020 Category: Research Source Type: news

bix_facilitates_global_partnerships
Boehringer Ingelheim: Digital Lab BI X Facilitates Global PartnershipsPartnerships play an essential role for BI X in creating digitally innovative products and services to accelerate the development of better healthcare for humans and animalsAmong other topics, BI X is searching for partners in the areas of complex neurological rehabilitation and single-cell multimodal omics technologiesSecond hub in Shanghai and new partnership platform to provide more cooperation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 30, 2020 Category: Research Source Type: news